[Ip-health] Patent holder on Breast Cancer Tests Denied Injunction in Lawsuit

Jamie Love james.love at keionline.org
Fri Mar 14 12:59:04 PDT 2014


Patent holder on Breast Cancer Tests Denied Injunction in Lawsuit
MARCH 10, 2014

Myriad Genetics, which lost a closely watched Supreme Court case last year
involving the patenting of genes, has suffered another setback in its
efforts to protect its main genetic test from competition.

A federal judge on Monday denied Myriad's request for a preliminary
injunction that would have immediately stopped a rival company, Ambry
Genetics, from offering a similar test.

Myriad's lucrative monopoly on testing for mutations in two genes linked to
breast cancer risk was shattered last June by the Supreme Court's ruling
that genes were not eligible for patents because they were products of

Several laboratory companies, including Ambry, quickly began offering
tests, in most cases undercutting the $4,000 Myriad charged for a full
analysis of the two genes, which are known as BRCA1 and BRCA2. Ambry
announced a price of $2,200.

Myriad sued most of these companies, contending their tests infringed other
patent claims that were not invalidated by the Supreme Court.

Justices, 9-0, Bar Patenting Human GenesJUNE 13, 2013
But Judge Robert J. Shelby of the United States District Court in Salt Lake
City said in an opinion on Monday that Ambry had raised "substantial
questions" concerning whether those remaining claims were eligible for
patents. He said therefore that Myriad had not established that it was
likely to succeed in the case on the merits of its arguments, which is a
legal requirement to win a preliminary injunction.

The upshot is that Ambry can continue to offer its test pending the outcome
of a trial or a settlement, said Dr. Robert M. Cook-Deegan, a research
professor at Duke University who has closely followed the case and the
issue of gene patents.

Charles Dunlop, chief executive of Ambry, called the ruling "a victory for
the entire genetics community." He said in a statement that Myriad's
lawsuit, after last year's Supreme Court decision, "was a blatant attempt
to maintain a monopoly state. We idealistically stood by our convictions
throughout this process and are exhilarated by today's ruling."

Ronald Rogers, a spokesman for Myriad, said Myriad looked forward to
presenting its case in court. Monday's ruling, he said in an email, "is a
denial of the preliminary injunction only" and "isn't a ruling on the
underlying merits of the case."

Myriad has not sought preliminary injunctions against GeneDx, Invitae,
Quest Diagnostics and Laboratory Corporation of America Holdings, which
have also started offering tests for BRCA1 and BRCA2. It probably cannot do
so now because Judge Shelby is also handing those cases.

The patent claims asserted by Myriad against Ambry included those for
primers, which are little pieces of DNA used to amplify genes, and methods
for analyzing the BRCA sequences.

Judge Shelby, in his 106-page opinion, agreed with Myriad's contention that
it would be harmed without the injunction because its ability to maintain
the price of its test would be undermined. Medicare has already proposed
cutting the reimbursement for Myriad's test roughly in half.

Myriad is joined in the suit by some other organizations that share in the
patent rights, including the University of Utah and the University of

A version of this article appears in print on March 11, 2014, on page B3 of
the New York edition with the headline: Patentholder on Breast Cancer Tests
Denied Injunction in Lawsuit.

James Love.  Knowledge Ecology International
http://www.keionline.org, KEI DC tel: +1.202.332.2670, US Mobile:
+1.202.361.3040, Geneva Mobile: +41.76.413.6584,   twitter.com/jamie_love

More information about the Ip-health mailing list